Halozyme Therapeutics Stock Analysis (NASDAQ:HALO)

Add to My Stocks
$12.51 $0.1 (0.79%) HALO stock closing price Feb 21, 2017 (Closing)
Watch Robo Advisor Video of HALO Stock Analysis
Halozyme Therapeutics
Updated on : Feb 21, 2017
previous close
HALO 12.5 (0%)
S&P 500 2365.4 (0%)
Closing Price On: Feb 21, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q3
$million
%
YOY GROWTH
Compared to the industry
Long Term Growth
5 Year CAGR:
22.8%
Operating Profit
Operating Margin:
-34.5%
Sector Average:
-1.1%
5 Quarter Net Profit
Net Margins
2016-Q3
%
LTM Margin
Cash Flow
Operating cash flow:
-$8.8M
Net Income:
-$29M
PROS      CONS
Recent Growth
Long Term Growth
Operating Margins
Net Margins
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
HALO PS :
10
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Free Cash Flow Margin:
-28.8%
Double Tap To Exit Full Screen
0:00
/

Halozyme Therapeutics Analysis Video

91 5 2

View Halozyme Therapeutics stock analysis video. This is our HALO analyst opinion covering the buy and sell arguments for HALO stock.

Halozyme Therapeutics, Inc. Stock Rating (2.3/5)

Our Halozyme Therapeutics stock opinion is based on fundamentals of the company. This Halozyme Therapeutics stock analysis is based on latest Q3 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy HALO stock?

  • The Year Over Year (YoY) revenue growth for Halozyme Therapeutics was 53.3% in 2016 Q3.
  • Long term revenue growth has been strong with a 5 year compounded annual growth of .

Should you sell HALO stock?

  • Over the last twelve months, Halozyme Therapeutics posted an average operating loss margin of -34.5%.
  • Over the last 12 months, Halozyme Therapeutics had an average Net loss of -44.6%.
  • PE ratio is meaningless for HALO stock as the company has losses.
  • HALO stock is trading at a PS multiple of 10, which is a negative when compared to the Medical-Biomed-Genetics industry average multiple of 4.6.
  • The company has negative Free Cash Flows (FCF), with a negative FCF margin of -28.8%.

Comments on this video and Halozyme Therapeutics stock